Here are four highlights:
1. Xtant anticipates its third quarter revenue to be between $23 million and $23.3 million.
2. This expected revenue represents a 10 percent to 11.5 percent increase compared to pro forma third quarter of 2015 revenue.
3. Additionally, the anticipated revenue reflects a sequential increase of 7.2 percent to 8.6 percent compared to second quarter 2016 revenue.
4. Xtant Medical manufactures regenerative medicine products.
More articles on devices:
Are Stryker’s hip implants about to be recalled?
Medtronic, Philips Healthcare lead US patient monitoring device market: 5 notes
SpineNevada offers advanced imaging with InMotion Diagnostics — 6 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
